貝曲西班作用機(jī)制 - Medchemexpress - MCE中國

1、Product Data SheetBetrixabanCat. No.: HY-10268CAS No.: 330942-05-7分式: CHClNO分量: 451.91作靶點(diǎn): Factor Xa作通路: Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 22 mg/mL (48.68 mM; Need ultrasonic and warming)SolventMass1 mg 5 mg 10 mgConcentra

2、tion制備儲(chǔ)備液1 mM 2.2128 mL 11.0641 mL 22.1283 mL5 mM 0.4426 mL 2.2128 mL 4.4257 mL10 mM 0.2213 mL 1.1064 mL 2.2128 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。BIOLOGICAL ACTIVITY物活性 Betrixaban種服有效的選擇性 factor Xa (fX

3、a) 抑制劑，IC50 為 1.5 nM。IC & Target IC50: 1.5 nM (fXa)1Ki: 0.117 nM (fXa), 1.8 M (hERG)1體外研究 In patch clamp hERG assays, Betrixaban has IC50 of 8.9 M. The plasma kallikrein IC50 and Ki values for Betrixaban are6.3 M and 3.5 M respectively. Betrixaban (hERG Ki 1.8 M) exhibits significantly lower hERG ac

4、tivity than all theothers (hERG Ki0.5 M)1.體內(nèi)研究Dosed at 0.5 mg/kg IV and 2.5 mg/kg PO, Betrixaban has bioavailability of 51.6% in dog; dosed at 0.75 mg/kg IV andPage 1 of 2 www.MedChemE7.5 mg/kg PO, Betrixaban has bioavailability of 58.7% in monkey1. Both Betrixaban and Apixa-ban-mediated whole-blood

5、 INR increases are similarly reversed by r-Antidote. After i.v. infusion of the three fXa inhibitors (eachadministered individually) for 30 min, the total plasma concentrations of rivaroxaban, Betrixaban and apixaban are1.40.4 M (means.d.), 0.20.01 M and 1.40.3 M, respectively, and the percentages o

6、f unbound inhibitor are2.2%0.8% (means.d.), 40%7.2% and 1.5%0.3%, respectively. After administration of r-Antidote, the total plasmaconcentrations of the inhibitors increased to 1.90.09 M, 2.00.4 M and 4.20.7 M, respectively, and thepercentage of unbound inhibitor declined to 0%, 0.3%0.1% and 0.05%0

7、.02%, respectively. Thus, for each of thethree inhibitors, correction of prothrombin time by r-Antidote to near-normal values is associated with a reduction inthe free fraction of the inhibitor2.PROTOCOLKinase Assay 2 To measure the inhibition of fXa activity by direct fXa inhibitors and the reversa

8、l of its inhibitory effect by r-Antidote,purified human plasma fXa (3 nM) (Haematologic Technologies), varying concentrations of inhibitor (0, 2.5, 5.0 and7.5 nM) and r-Antidote are added to the assay buffer (20 mM Tris, 150 mM NaCl, 5 mM Ca2+ and 0.1% BSA, pH 7.4).After incubation at room temperatu

9、re for 30 min, 100 M Spectrozyme-fXa is added to the mixture, and the initialrate of substrate cleavage is monitored continuously for 5 min at 405 nm in a 96-well plate reader. The initialvelocity of product formation as a function of inhibitor and r-Antidote concentrations is analyzed by Dynafit to

10、estimate the binding affinity of r-Antidote to each inhibitor2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Rats2Administration 2 Whole-blood INR values (means.d.) in rats infused with Betrixaban (1 mg/kg per hour) or vehicle and then treatedw

11、ith either vehicle or r-Antidote by i.v. bolus (6 mg) over 5 min plus infusion (9 mg/h) for up to 90 min. Circles,vehicle+vehicle; squares, Betrixaban + vehicle; triangles, Betrixaban + r-Antidote. *P0.02 compared to the r-Antidote treatment group determined by unpaired two-tailed t test. Whole-bloo

12、d INR values (means.d.) in ratsinfused with Apixaban (0.5 mg per kg body weight h1) or vehicle and then treated with either vehicle or r-Antidoteby i.v. bolus (6 mg) over 5 min plus infusion (6 mg/h) for up to 90 min. Circles, vehicle + vehicle; squares, apixaban +vehicle; triangles, apixaban+r-Anti

13、dote. *P0.01 compared to the r-Antidote treatment group determined byunpaired two-tailed t test.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Thromb Haemostasis. 2019 May 16:111950. Int J Lab Hematol. 2019 Jan 3.See more customer validatio

14、ns on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Zhang P, et al. Discovery of Betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, ahighly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):212. Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19(4):446-51.McePdfHeightPage 2 of 3 ww